GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSK evidence brief
What we can confirm
- Market Cap:
- $94.23B
What it means
What to watch
Prepared research question
What matters most for GSK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GSK
GSK plc is a global pharmaceutical company advancing a pipeline focused on respiratory, oncology, and specialty therapies, while pursuing cost savings to offset upcoming HIV patent expirations.
Key risk: HIV patent cliff
Market Cap
$94.23B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 3 clinical trials for GSK plc American Depositary Shares (Each representing two Ordinary Shares).
GSK plc is a global pharmaceutical company advancing a pipeline focused on respiratory, oncology, and specialty therapies, while pursuing cost savings to offset upcoming HIV patent expirations.
- GSK reported Q2 2026 turnover of £8.4 billion, a 5% increase year-over-year at constant exchange rates [news · published 2026-08-13].
- The company is targeting £1.9 billion in cost savings to support pipeline investment and navigate HIV patent expirations [news · published 2026-09-13].
- GSK has entered multiple partnerships in 2026, including a $750 million deal for a trispecific T-cell engager from Chimagen Biosciences [news · published 2026-09-24].
- The company is expanding its oncology pipeline into hematologic malignancies, gynecologic cancers, lung cancer, and prostate cancer [news · published 2026-09-16].
- GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics and AI-driven patient selection [news · published 2026-09-23].
What works
- GSK's pipeline has been strengthened through multiple partnerships and licensing deals in 2026, including a $750 million acquisition of a trispecific T-cell engager [news · published 2026-09-24].
- The company reported strong Q2 2026 financial performance with 5% revenue growth and 7% core operating profit growth at constant exchange rates [news · published 2026-08-13].
- GSK is pursuing a focused oncology expansion across multiple tumor types, supported by both internal research and business development [news · published 2026-09-16].
What to weigh
- GSK faces upcoming HIV patent expirations that could pressure profitability, prompting a £1.9 billion cost-saving program [news · published 2026-09-13].
- The company trades at a discount to pharma peers, with one analyst noting it trades 42% below pharma peers [news · published 2026-07-21].
- GSK's pipeline acceleration relies on costly business development deals, such as the $750 million Chimagen Biosciences acquisition, which may strain financial resources [news · published 2026-09-24].
From the filings
Quoted directly from source documents.
GSK is targeting £1.9 billion in cost savings to support pipeline investment and navigate HIV patent expirations.
“GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff”
News · September 13, 2026
GSK reported Q2 2026 turnover of £8.4 billion, a 5% increase year-over-year at constant exchange rates.
“The firm’s total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER)”
News · August 13, 2026
GSK has agreed to acquire full global rights to a trispecific T-cell engager from Chimagen Biosciences in a deal worth up to $750 million.
“The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million.”
News · September 24, 2026
GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics and AI.
“GSK (NYSE:GSK) is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches”
News · September 23, 2026
Risks & what to watch (3)›
Key risks
- HIV patent cliff — Upcoming HIV patent expirations could pressure profitability; GSK is targeting £1.9B in savings to mitigate [news · published 2026-09-13].
- Pipeline reliance on M&A — Costly deals like the $750M Chimagen acquisition may strain financial resources if pipeline candidates fail [news · published 2026-09-24].
- Valuation discount — GSK trades 42% below pharma peers, indicating potential market skepticism about growth prospects [news · published 2026-07-21].
What to watch
- FDA decision on bepirovirsen expected in October 2026 [news · published 2026-08-27].
- Phase 3 OCEAN results for an undisclosed candidate [news · published 2026-08-27].
- Progress of the $750 million trispecific T-cell engager deal with Chimagen Biosciences [news · published 2026-09-24].
- Execution of the £1.9 billion cost-saving program and its impact on pipeline investment [news · published 2026-09-13].
Sources: Catalysts · News · Generated October 13, 2026 · How we verify sources →
Run GSK plc American Depositary Shares (Each representing two Ordinary Shares) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GSK plc American Depositary Shares (Each representing two Ordinary Shares) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,022
Total value held
$18.90B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 67,661,646 | $3.73B |
| dodge & cox | 58,662,974 | $3.24B |
| fisher asset management, llc | 34,522,363 | $1.91B |
| primecap management co/ca/ | 25,204,538 | $1.39B |
| wellington management group llp | 11,717,613 | $646.7M |
| morgan stanley | 11,030,651 | $608.8M |
| goldman sachs group inc | 9,589,114 | $529.2M |
| royal bank of canada | 7,506,786 | $414.3M |
| state street corp | 5,998,486 | $334.0M |
| holocene advisors, lp | 5,518,433 | $304.6M |
Showing top 10 of 1,022 institutional holders of GSK plc American Depositary Shares (Each representing two Ordinary Shares). Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 0.8%
- Days to cover
- 3.4
- Shares short
- 16,061,751
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GSK short interestGovernance
Frequently asked questions
What is the AI investment thesis for GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
GSK plc is a global pharmaceutical company advancing a pipeline focused on respiratory, oncology, and specialty therapies, while pursuing cost savings to offset upcoming HIV patent expirations.
Who is the CEO of GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
Mr. Luke Victor Miels is the chief executive officer of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK).
Where is GSK plc American Depositary Shares (Each representing two Ordinary Shares) headquartered?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is headquartered in London, United Kingdom.
What therapeutic areas does GSK plc American Depositary Shares (Each representing two Ordinary Shares) focus on?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.